IDEAYA Biosciences Inc. (IDYA)
| Bid | 12.51 |
| Market Cap | 1.5B |
| Revenue (ttm) | 7M |
| Net Income (ttm) | -274.48M |
| EPS (ttm) | -3.36 |
| PE Ratio (ttm) | -5.1 |
| Forward PE | -8.81 |
| Analyst | Buy |
| Ask | 18.5 |
| Volume | 1,233,990 |
| Avg. Volume (20D) | 1,110,991 |
| Open | 17.16 |
| Previous Close | 16.75 |
| Day's Range | 16.32 - 17.27 |
| 52-Week Range | 13.45 - 44.42 |
| Beta | 0.51 |
About IDYA
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, ...
Analyst Forecast
According to 13 analyst ratings, the average rating for IDYA stock is "Buy." The 12-month stock price forecast is $53, which is an increase of 209.40% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study ComingIdeaya Biosciences, Inc.'s darovasertib + crizotinib combination is being explored in the potential registration-enabling phase 2/3 study targeting patients with 1st-line HLA-A2-negative metastatic uv...
